Magnesium prevents acute hypercalcemic hypertension.
Systolic and mean blood pressures were shown to increase from means of 159 +/- 7 and 111 +/- 7 mm Hg to 174 +/- 8 and 122 +/- 6 mm Hg, respectively (p less than 0.05 in each case), after a 2-hour intravenous infusion of CaCl2 during which serum magnesium levels were found to decrease from 1.8 +/- 0.06 to 1.4 +/- 0.05 mg/dl (p less than 0.0005). A significant increase in blood pressure was not seen when MgSO4 was given intravenously concomitantly with the CaCl2 so that serum magnesium levels did not decline. We conclude that hypercalcemic hypertension is due in part to altered serum magnesium and is prevented if serum magnesium is sustained.
Zawada
E T
ET
University of South Dakota School of Medicine, Sioux Falls.
TerWee
J A
JA
McClung
D E
DE
D000208:Acute Disease; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006934:Hypercalcemia / Q000150:complications* / Q000503:physiopathology; D006973:Hypertension / Q000503:physiopathology / Q000517:prevention & control*; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D008278:Magnesium Sulfate